MucoLife Therapeutics wins Swedish grant for inhaled mucus-dissolving therapy
What's the deal? Swedish startup MucoLife Therapeutics has been awarded funding from Medtech4Health and Vinnova, Sweden's innovation agency, through the "Kompetensförstärkning i småföretag 2026" programme. The grant will support development planning for a nebulisation device designed to deliver MLT-001, the company's lead therapeutic candidate — a first-in-class inhaled therapy that rapidly dissolves pathological mucus plugs in the lungs.
MLT-001 targets both acute and chronic respiratory diseases, including COPD, cystic fibrosis, and severe respiratory distress. The planned nebuliser is intended for hospitals, intensive care units, home care, and crisis-response scenarios.
Why now? MucoLife is using the grant to bring in external expertise in nebulisation technology, regulatory strategy, and sustainable product development — building internal capabilities before moving to prototype development. The project aims to create a technical, regulatory, and commercial roadmap for a platform that serves both routine healthcare and emergency preparedness.
"This project represents an important step toward enabling rapid and effective delivery of MLT-001 in both routine healthcare and emergency settings, while integrating sustainability and preparedness considerations from the outset," said Thaher Pelaseyed, chief executive officer of MucoLife Therapeutics.
What could go wrong? Inhaled drug delivery is notoriously complex — getting the right particle size, dose consistency, and regulatory clearance for a dual-use device across multiple clinical settings adds layers of risk. MucoLife is still at the development-planning stage, meaning prototype development, clinical trials, and commercialisation lie ahead.
The signal: The grant reflects Sweden's continued push to back early-stage medtech through public innovation funding. It also points to growing interest in dual-use health technologies that serve both everyday clinical needs and emergency preparedness — a theme that has gained traction since the pandemic exposed gaps in respiratory care infrastructure.
Read more: nordiclifescience.org
